Abstract
Twenty patients, of both sexes, suffering from ischaemic heart disease and/or atherosclerotic peripheral vascular disease have been studied in a long-term trial of tetranicotinoylfructose (Bradilan) by mouth.
Cholesterol levels fell in Type II cases and triglycerides in Type IV, the falls being well maintained at 6 months. Significant falls in fibrinogen, free fatty acids, and platelet stickiness were also observed and maintained at 6 months. Fibrinolytic activity increased significantly and over a similar period of time. These results bore no relation to Fredrickson types.
Only one important side-effect, namely flushing, was observed. It was infrequent and tolerable and it diminished with time and adjustment of dosage.
Get full access to this article
View all access options for this article.